The inhibitory effects of xanthohumol, a prenylated chalcone derived from hops, on cell growth and tumorigenesis in human pancreatic cancer

Biomedicine and Pharmacotherapy

Volumn 73, Issue , 2015, Pages 40-47

  Jiang, Weiliang ^a   Zhao, Senlin ^a   Xu, Ling ^a   Lu, Yingying ^a   Lu, Zhanjun ^a   Chen, Congying ^a   Ni, Jianbo ^a   Wan, Rong ^a   Yang, Lijuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Pancreatic cancer; STAT3 signaling; Xanthohumol

Indexed keywords

KI 67 ANTIGEN; MESSENGER RNA; PROTEIN BCL XL; STAT3 PROTEIN; SURVIVIN; XANTHOHUMOL; ANTINEOPLASTIC AGENT; CHALCONE; FLAVONOID; PROPIOPHENONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HUMULUS; ISOLATION AND PURIFICATION; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; PRENYLATION; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHALCONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; HUMANS; HUMULUS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PRENYLATION; PROPIOPHENONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937805807     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.05.020     Document Type: Article

References (37)

1. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
2. Ying J.E., Zhu L.M., Liu B.X. Developments in metastatic pancreatic cancer: is gemcitabine still the standard?. World J. Gastroenterol. 2012, 18:736-745.
3. Gresham G.K., Wells G.A., Gill S., Cameron C., Jonker D.J. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer 2014, 14:471.
4. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 2015, 65:5-29.
5. Gerhauser C., Alt A., Heiss E., Gamal-Eldeen A., Klimo K., Knauft J., et al. Cancer chemopreventive activity of Xanthohumol, a natural product derived from hop. Mol. Cancer Ther. 2002, 1:959-969.
6. Lust S., Vanhoecke B., Van Gele M., Boelens J., Van Melckebeke H., Kaileh M., et al. Xanthohumol activates the proapoptotic arm of the unfolded protein response in chronic lymphocytic leukemia. Anticancer Res. 2009, 29:3797-3805.
7. Monteghirfo S., Tosetti F., Ambrosini C., Stigliani S., Pozzi S., Frassoni F., et al. Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation. Mol. Cancer Ther. 2008, 7:2692-2702.
8. Monteiro R., Calhau C., Silva A.O., Pinheiro-Silva S., Guerreiro S., Gartner F., et al. Xanthohumol inhibits inflammatory factor production and angiogenesis in breast cancer xenografts. J. Cell. Biochem. 2008, 104:1699-1707.
9. Pan L., Becker H., Gerhauser C. Xanthohumol induces apoptosis in cultured 40-16 human colon cancer cells by activation of the death receptor- and mitochondrial pathway. Mol. Nutr. Food Res. 2005, 49:837-843.
10. Araujo J.R., Goncalves P., Martel F. Chemopreventive effect of dietary polyphenols in colorectal cancer cell lines. Nutr. Res. 2011, 31:77-87.
11. Drenzek J.G., Seiler N.L., Jaskula-Sztul R., et al. Xanthohumol decreases Notch1 expression and cell growth by cell cycle arrest and induction of apoptosis in epithelial ovarian cancer cell lines. Gynecol. Oncol. 2011, 122:396-401.
12. Festa M., Capasso A., D'Acunto C.W., Masullo M., Rossi A.G., Pizza C., et al. Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways. J. Nat. Prod. 2011, 74:2505-2513.
13. Dorn C., Weiss T.S., Heilmann J., Hellerbrand C., Xanthohumol a prenylated chalcone derived from hops, inhibits proliferation, migration and interleukin-8 expression of hepatocellular carcinoma cells. Int. J. Oncol. 2010, 36:435-441.
14. Ho Y.C., Liu C.H., Chen C.N., Duan K.J., Lin M.T. Inhibitory effects of xanthohumol from hops (Humulus lupulus L.) on human hepatocellular carcinoma cell lines. Phytother. Res. 2008, 22:1465-1468.
15. Vene R., Benelli R., Minghelli S., Astigiano S., Tosetti F., Ferrari N. Xanthohumol impairs human prostate cancer cell growth and invasion and diminishes the incidence and progression of advanced tumors in TRAMP mice. Mol. Med. 2012, 18:1292-1302.
16. Colgate E.C., Miranda C.L., Stevens J.F., Bray T.M., Ho E. Xanthohumol, a prenylflavonoid derived from hops induces apoptosis and inhibits NF-kappaB activation in prostate epithelial cells. Cancer Lett. 2007, 246:201-209.
17. Goto K., Asai T., Hara S., Namatame I., Tomoda H., Ikemoto M., et al. Enhanced antitumor activity of xanthohumol, a diacylglycerol acyltransferase inhibitor, under hypoxia. Cancer Lett. 2005, 219:215-222.
18. Kim S.J., Jung K.H., Yan H.H., Son M.K., Fang Z., Ryu Y.L., et al. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation. Oncotarget 2015, 6:1507-1518.
19. Zhang T., Chen Y., Li J., Yang F., Wu H., Dai F., et al. Antitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer. Neoplasia 2014, 16:665-677.
20. Thoennissen N.H., Iwanski G.B., Doan N.B., Lin P., Abbassi S., Song J.H., et al. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res. 2009, 69:5876-5884.
21. Jamieson N.B., Carter C.R., McKay C.J., Oien K.A. Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin. Cancer Res. 2011, 17:3316-3331.
22. Corcoran R.B., Contino G., Deshpande V., Tzatsos A., Conrad C., Benes C.H., et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 2011, 71:5020-5029.
23. Scholz A., Heinze S., Detjen K.M., Peters M., Welzel M., Hauff P., et al. Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology 2003, 125:891-905.
24. Venkatasubbarao K., Peterson L., Zhao S., Hill P., Cao L., Zhou Q., et al. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. Mol. Cancer 2013, 12:104. 10.1186/1476-4598-12-104.
25. Bromberg J., Darnell J.E. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000, 19:2468-2473.
26. Bowman T., Garcia R., Turkson J., Jove R. STATs in oncogenesis. Oncogene 2000, 19:2474-2488.
27. Darnell J.E. STATs and gene regulation. Science 1997, 277:1630-1635.
28. Mackenzie G.G., Huang L., Alston N., Ouyang N., Vrankova K., Mattheolabakis G., et al. Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice. Plos One 2013, 8:e61532.
29. Glienke W., Maute L., Wicht J., Bergmann L. Curcumin inhibits constitutive STAT3 phosphorylation in human pancreatic cancer cell lines and downregulation of survivin/BIRC5 gene expression. Cancer Invest. 2010, 28:166-171.
30. Kang Y., Park M.A., Heo S.W., Park S.Y., Kang K.W., Park P.H., et al. The radio-sensitizing effect of xanthohumol is mediated by STAT3 and EGFR suppression in doxorubicin-resistant MCF-7 human breast cancer cells. Biochim. Biophys. Acta 2013, 1830:2638-2648.
31. DeArmond D., Brattain M.G., Jessup J.M., Kreisberg J., Malik S., Zhao S., et al. Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines. Oncogene 2003, 22:7781-7795.
32. Zhang Y.Q., Bharadwaj U., Logsdon C.D., Chen C.Y., Yao Q.Z., Li M. ZIP4 regulates pancreatic cancer cell growth by activating IL-6/STAT3 pathway through zinc finger transcription factor CREB. Clin. Cancer Res. 2010, 16:1423-1430.
33. Altieri D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 2008, 8:61-70.
34. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
35. Gritsko T., Williams A., Turkson J., Kaneko S., Bowman T., Huang M., et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. 2006, 12:11-19.
36. Vanhoecke B.W., Delporte F., Van Braeckel E., Heyerick A., Depypere H.T., Nuytinck M., et al. A safety study of oral tangeretin and xanthohumol administration to laboratory mice. In Vivo 2005, 19:103-107.
37. Hussong R., Frank N., Knauft J., Ittrich C., Owen R., Becker H., et al. A safety study of oral xanthohumol administration and its influence on fertility in Sprague-Dawley rats. Mol. Nutr. Food Res. 2005, 49:861-867.